| Biomarker ID | 827 |
| PMID | 22146597 |
| Year | 2011 |
| Biomarker | Auto-antibody signature (TARDBP, TLN1, PARK7, LEDGF/ PSIP1, and CALD1) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(TLN1):-Collagen binding in corneal epithelia mediated by Erk and PI-3 Kinase,Mammalian calpain regulation of cell motility,Nectin adhesion pathway,Muscle contraction,Platelet aggregation (plug formation) |
| Experiment | prostate cancer Vs benign prostatic hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | Prostate cancer patient serum samples (n=41) and BPH patient samples without the diagnosis of cancer (n=39) were obtained |
| Senstivity | 95% |
| Specificity | 80% |
| AUC | 0.95 |
| Accuracy | NA |
| Level Of Significance | p< 0.05 |
| Method Used | BCA Protein Assay |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | TARDBP, TLN1, PARK7, PSIP1, CALD1 |